STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy

M.D. Anderson Cancer Center980 enrolled

Overview

To learn if monitoring blood levels of heart injury (troponin levels) in cancer participants treated with immune checkpoint inhibitors will lead to decreased heart-related side effects.

Primary Objectives: * Myocarditis CTCAE version 5.0 grade ≥ 3 * Ventricular tachycardia (≥ 30 seconds) * Advanced atrioventricular block * Incident heart failure event * Cardiovascular mortality * Non-fatal sudden cardiac arrest * Acute coronary syndrome * Pericarditis * Pericardial tamponade Secondary Objectives: * Time from symptom onset to diagnosis of major adverse cardiovascular events * Time from symptom onset to diagnosis of myocarditis * Initial hospitalization duration for the adverse cardiovascular event from primary endpoint * Peak biomarker levels including troponin T, troponin I, creatine kinase, and creatine kinase myocardial band * Percentage of patients with negative workup for myocarditis * Percentage of patients requiring major cardiac testing including echocardiograms, cardiac magnetic resonance imaging, and/or invasive heart catheterization * Duration of interruption and/or discontinuation of immune checkpoint inhibitor therapy * Cancer progression free survival * Time to next cancer therapy

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SCREENING

Masking

NONE

Enrollment

980

Conditions

Immune Checkpoint Therapy

Interventions

Troponin surveillanceDIAGNOSTIC_TEST

Troponin will be monitored prior to each immune checkpoint inhibitor infusion for the first 12 weeks of therapy.

Standard of careOTHER

Standard of care if symptoms arise then evaluation with cardiac biomarkers and/or further cardiac testing.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female patient ≥18 years old * Plan for treatment with an immune checkpoint inhibitor as standard of care even if patient is also on an additional investigational cancer therapeutic * Willingness to provide informed consent Exclusion Criteria: * Troponin T not available at screening or prior to randomization * Inability to comply with planned study procedures * Major adverse cardiovascular event included in the primary outcome within the 30 days prior to enrollment * Any medical condition that could interfere with, or for which the treatment might interfere with the conduct of the study or interpretation of the study results, or that would, in the opinion of the investigator, increase the risk of the participant by participating in the study * Any factors that, in the Investigator's opinion, are likely to interfere with study procedures, such as history of noncompliance with scheduled appointments.

Locations (1)

MD Anderson Cancer Center

Houston, Texas, United States

RECRUITING

Outcomes

Primary Outcomes

Safety and adverse events (AEs)

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)

Time frame: Through study completion; an average of 1 year.

Central Contacts

Nicolas Palaskas, MD

CONTACT

(713) 606-3957 nlpalaskas@mdanderson.org

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.